Navigation Links
Diabetic stroke risk after AMI drops in 10 year period
Date:8/31/2013

The findings were presented at the ESC Congress today by Ms Stina Jakobsson from Sweden. They reveal that reperfusion therapy and secondary prevention drugs produced the decline and brought stroke risk after AMI closer to that of non-diabetics.

Ms Jakobsson said: "Ischemic stroke following an acute myocardial infarction is a fairly uncommon but devastating event with high mortality. It has long been recognized that patients with diabetes mellitus are at a particularly high risk of complications after an AMI but until now, the risk of ischemic stroke after an AMI in patients with diabetes has been uncertain."

The study included 173,233 patients registered as having their first AMI during 1998-2008 in the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA). RIKS-HIA contains data on all patients admitted to Sweden's 74 coronary care units.

During 1998-2008, of the 33,503 (19%) patients in the register who had a previous diagnosis of diabetes, 5.5% had an ischemic stroke within one year after the AMI. This compared to a stroke rate of 3.5% in patients on the register who did not have diabetes and 0.3% in the Swedish general population (who were not on the register and had no history of AMI). Ms Jakobsson said: "We believe that an important mechanism behind the increased risk for ischemic stroke after an AMI, especially in diabetic patients, may be increased inflammation and platelet reactivity seen with an AMI."

Ischemic stroke rate decreased over time (see figure 1). During 1998-2000, 7.1% of diabetic patients had an ischemic stroke within one year after their first AMI, compared to 4.7% during 2007-2008. A smaller decline was observed in non-diabetic patients, from 4.2% in 1998-2000 to 3.7% in 2007-2008.

In the diabetics, prior reperfusion therapy with coronary angioplasty, coronary angioplasty during the AMI hospital stay, and prescription of the secondary preventive medications acetylsalicylic acid, P2Y12-inhibitors and statins when leaving hospital were independently associated with the reduced stroke risk over time.

Higher age, prior ischemic stroke, a specific type of myocardial infarction (ST-elevation MI) and atrial fibrillation during the hospitalization were found to be risk factors for an ischemic stroke within one year after AMI in patients with diabetes.

The study found that despite the greater improvements in stroke risk seen in diabetic patients, they were treated to a lesser extent than non-diabetic patients with reperfusion therapies during their initial hospital stay. They also left hospital with less standard medication for secondary prevention after an AMI. During the entire study period, the prescription of secondary preventive medication increased in both diabetic and non-diabetic patients.

Ms Jakobsson said: "The decreased ischemic stroke rate in both patient groups over time may be explained by a reduction in established risk factors for stroke and increased use of secondary preventive treatments after AMI. The larger reduction in stroke risk seen in diabetic patients may indicate that they gained more from the greater use of secondary preventive medication. But secondary preventive treatments are still underutilized in diabetic patients and there is room for increased use."


'/>"/>

Contact: Celine Colas
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Study reveals how cancer drug causes diabetic-like state
2. Diabetic retinopathy research could reduce screening costs
3. Correct treatment of common diabetic foot infections can reduce amputations
4. Middle-Aged Diabetics May Need Earlier Colon Checks
5. Personalized Blood Pressure Therapy May Help Diabetics
6. Wayne State University researcher examines proteins role in diabetic retinopathy
7. Sleep apnea linked to increased risk for carbohydrate craving among diabetics
8. Sleep Apnea May Spur Carb Cravings in Diabetics
9. Obstructive sleep apnea is associated with diabetic peripheral neuropathy
10. Sleep Apnea May Be Linked to Nerve Damage in Diabetics
11. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – with a ... lifting weights for strength training and exercise or simply lifting heavy objects, advises Dr. ... position is everything,” Dr. Chang says. “Improper technique in lifting anything heavy or an ...
(Date:5/23/2017)... New York City (PRWEB) , ... May 23, ... ... Record (EHR), Population Health and Clinical Integration company, announced today that its ... Patient-Centered Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network and the ... Center for Women’s Behavioral Health at West Penn Hospital , a unique facility ... suffering from pregnancy-related depression. Construction of the Center is underway with a scheduled ...
(Date:5/23/2017)... ... 2017 , ... Cambridge, MA, May 23, 2017—Total costs per ... a Workers Compensation Research Institute (WCRI) study, a contrast from the increases of ... Benchmarks, 17th Edition looks at indemnity and medical payments for workers’ compensation ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i ... 2017 Best in KLAS category winner, has named Daniel P. Bullington as chief ... enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel is ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology: